Taglutimide is a norbornane derivative patented by Kwizda, F. Joh., Chemische Fabrik as the sedative-hypnotic compound. In preclinical studies, Taglutimide did not produce any toxic effects when administered orally to mice even at a very high dosage. Central-nervous depression was demonstrated by a reduction in spontaneous motor activity, potentiation of the central-depressant effect of pentobarbital, antagonism of the central-stimulant effect of amphetamine after oral administration and by narcotic activity after i.v. administration of the drug. Furthermore, oral administration of Taglutimide potentiated the analgesic action of morphine without being effective on its own.